People · Operator
Named in public records as an officer, director or promoter · active 2011–2017 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xcellerex, Inc. | — | Other | Seed | $2.0M | $36.4M | 2011 |
| US Biologic, Inc. | — | Biotechnology | Pre-Seed | $1.0M | $55.2M | 2017 |
Thomas Monath at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Monath on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Williams | 1 | 17 |
| Joseph Zakrzewski | 1 | 6 |
| Tommy Thompson | 1 | 5 |
| Guy Broadbent | 1 | 3 |
| David J. Williams | 1 | 3 |
| Jon Lieber | 1 | 2 |
| Douglas J. Treco | 1 | 1 |
| Michael Shmerling | 1 | 1 |
| Mason Kauffman | 1 | 1 |
| Chris Przybyszewski | 1 | 1 |
| Scot Galliher | 1 | 1 |
| Boris Lipkin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.